Australia's most trusted
source of pharma news
Posted 25 February 2026 PM
HCPs in oncology have started valuing a broad portfolio of drugs when evaluating pharmas in the segment rather than huge blockbusters, according to the latest survey released by ZoomRx.
In the most recent survey asking HCPs to rank 20 pharmas across five weighted dimensions AstraZeneca maintained top position by "offering a breadth of innovation that few can match" with deep pipelines across multiple tumour types, backed up by responsive support teams. It had an overall score of 47.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.